NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

n=8), weekly exenatide injections (Bydureon BCise®, n=8), or weekly 1 mg semaglutide injections (Wegovy®, n=8) for a 9-week treatment duration. Changes in weight will be measured. The study is ...

AstraZeneca Plc's (NASDAQ:AZN) Bydureon BCise (exenatide 2 mg prolonged-release suspension for injection) is indicated for type-2 diabetes. Novo Nordisk A/S' (NYSE:NVO) semaglutide is approved as ...

weekly injections of AstraZeneca’s branded exenatide medication for diabetes Bydureon BCise, or weekly Wegovy doses. Vivani ...

Participants will undergo an initial phase with semaglutide injections before being randomized into three groups, receiving either a single administration of the exenatide implant, weekly exenatide ...

n=8), weekly exenatide injections (Bydureon BCise®, n=8), or weekly 1 mg semaglutide injections (Wegovy®, n=8) for a 9-week treatment duration. Changes in weight will be measured. The study is ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

It was made into a drug called exenatide and in 2005 ... which was a daily injection, and long-acting GLP-1 agonists such as semaglutide, a weekly injection. As well as increasing insulin from ...

Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...